IN VITRO SUSCEPTIBILITY OF BORRELIA AFZELII, THE CAUSATIVE AGENT OF LYME BORRELIOSIS, TO THE SUPERNATANTS OF LACTIPLANTIBACILLUS PLANTARUM AND SACCHAROMYCES BOULARDII
Abstract
Introduction: Lyme borreliosis (LB) is a multisystem disorder caused by bacteria of the Borrelia burgdorferi sensu lato complex, transmitted to humans through the bite of Ixodes spp. ticks. Standard treatment typically involves prolonged antibiotic therapy. Currently, no topical product is available on the market for prophylactic use following a tick bite.
Aim: The aim of the study was to investigate in vitro the effects of supernatants derived from the probiotic microorganisms Saccharomyces boulardii and Lactiplantibacillus plantarum, and their mixtures, on the growth and motility of Borrelia afzelii.
Materials and methods: To test the susceptibility of Borrelia afzelii to probiotic microorganisms, a modified broth microdilution method adapted for Borrelia species was employed. Minimum inhibitory concentrations (MICs) were determined by evaluating both the number and motility of B. afzelii after 72 hours of incubation with supernatants under anaerobic conditions, compared to a positive control consisting of untreated B. afzelii culture.
Results: The MIC was defined as the lowest concentration of the tested supernatant at which borrelia were non-motile and their number was reduced compared to the positive control. The following median MIC values were determined: 12.5% for S. boulardii, 6% for L. plantarum, and the lowest median MIC value of 0.8% was defined for the supernatant mixture of probiotic microorganisms.
Conclusion: The mixture of Saccharomyces boulardii and Lactiplantibacillus plantarum exhibited the strongest inhibitory effect on the growth and motility of Borrelia afzelii. These results provide a foundation for further investigation into the molecular mechanisms of the inhibitory activity of probiotic microorganisms against Borrelia species.
References
Stanek G, Strle F. Lyme borreliosis – from tick bite to diagnosis and treatment. FEMS Microbiol Rev. 2018;42(3):233-58. doi: 10.1093/femsre/fux047.
Stanek G, Wormser GP, Gray J, Strle F. Lyme borreliosis. The Lancet. 2012 Feb;379(9814):461-73. doi: 10.1016/s0140-6736(11)60103-7.
Sykes RA, Makiello P. An estimate of Lyme borreliosis incidence in Western Europe. J Public Health. 2016 Mar 9;fdw017. doi: 10.1093/pubmed/fdw017.
Geebelen L, Lernout T, Devleesschauwer B, Kabamba-Mukadi B, Saegeman V, Belkhir L, et al. Non-specific symptoms and post-treatment Lyme disease syndrome in patients with Lyme borreliosis: a prospective cohort study in Belgium (2016–2020). BMC Infect Dis. 2022 Sep 28;22(1):756. doi: 10.1186/s12879-022-07686-8.
Estrada-Peña A, Cutler S, Potkonjak A, Vassier-Tussaut M, Van Bortel W, Zeller H, et al. An updated meta-analysis of the distribution and prevalence of Borrelia burgdorferi s.l. in ticks in Europe. Int J Health Geogr. 2018 Dec;17(1):41. doi: 10.1186/s12942-018-0163-7.
Ćakić S, Veinović G, Cerar T, Mihaljica D, Sukara R, Ružić‐Sabljić E, et al. Diversity of Lyme borreliosis spirochetes isolated from ticks in Serbia. Med Vet Entomol. 2019 Dec;33(4):512-20. doi: 10.1111/mve.12392.
Milutinović M, Masuzawa T, Tomanović S, Radulović Ž, Fukui T, Okamoto Y. Borrelia burgdorferi sensu lato, Anaplasma phagocytophilum, Francisella tularensis and their co-infections in host-seeking Ixodes ricinus ticks collected in Serbia. Exp Appl Acarol. 2008 Aug;45(3–4):171-83. doi: 10.1007/s10493-008-9166-6.
Mladenović J. Epidemiološki Aspekti Lajmske Bolesti na Teritorije Građa Beograda. Medicinski fakultet, Univerziteta u Nišu; 2014.
Steere AC, Strle F, Wormser GP, Hu LT, Branda JA, Hovius JWR, et al. Lyme borreliosis. Nat Rev Dis Primer. 2016 Dec 15;2(1):16090. doi: 10.1038/nrdp.2016.90.
Cohrssen A. KB. Probiotics [Internet]. American Family Physician; 2008. Available from: https://www.aafp.org/pubs/afp/issues/2008/1101/p1073.html.
Garcia-Gonzalez N, Battista N, Prete R, Corsetti A. Health-Promoting Role of Lactiplantibacillus plantarum Isolated from Fermented Foods. Microorganisms. 2021 Feb 10;9(2):349. doi: 10.3390/microorganisms9020349.
Ali MAE, Abdel-Fatah OM, Janson JC, Elshafei AM. Antimicrobial potential of Saccharomyces boulardii extracts and fractions. J Appl Sci Res. 2012;8(8):4537-43.
Kelesidis T, Pothoulakis C. Efficacy and safety of the probiotic Saccharomyces boulardii for the prevention and therapy of gastrointestinal disorders. Ther Adv Gastroenterol. 2012 Mar;5(2):111-25. doi: 10.1177/1756283x11428502.
Fidanza M, Panigrahi P, Kollmann TR. Lactiplantibacillus plantarum–Nomad and Ideal Probiotic. Front Microbiol. 2021 Oct 6;12:712236. doi: 10.3389/fmicb.2021.712236.
Echegaray N, Yilmaz B, Sharma H, Kumar M, Pateiro M, Ozogul F, et al. A novel approach to Lactiplantibacillus plantarum: From probiotic properties to the omics insights. Microbiol Res. 2023 Mar;268:127289. doi: 10.1016/j.micres.2022.127289.
Murray CJL, Ikuta KS, Sharara F, Swetschinski L, Robles Aguilar G, Gray A, et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. The Lancet. 2022 Feb;399(10325):629-55. doi: 10.1016/S0140-6736(21)02724-0.
Veinović G. Uticaj uslova kultivisanja na rast, razmnožavanje, preživljavanje i morfološke odlike vrsta Borrelia afzelii, Borrelia garinii i Borrelia burgdorferi sensu stricto. Farmaceutski fakultet, Univerzitet u Beogradu; 2013.
Veinović G, Cerar T, Strle F, Lotrič-Furlan S, Maraspin V, Cimperman J, et al. In vitro susceptibility of European human Borrelia burgdorferi sensu stricto strains to antimicrobial agents. Int J Antimicrob Agents. 2013 Mar;41(3):288-91. doi: 10.1016/j.ijantimicag.2012.11.016.
De Carvalho BT, Subotić A, Vandecruys P, Deleu S, Vermeire S, Thevelein JM. Enhancing probiotic impact: engineering Saccharomyces boulardii for optimal acetic acid production and gastric passage tolerance. Nygård Y, editor. Appl Environ Microbiol. 2024 Jun 18;90(6):e00325-24. doi: doi.org/10.1128/aem.00325-24.
Rajkowska K, Kunicka-Styczyńska A. Probiotic activity of Saccharomyces cerevisiae var. boulardii against human pathogens [master's thesis]. Zagreb: University of Zagreb, Faculty of Food Technology and Biotechnology; 2012.
De Simone N, Rocchetti MT, La Gatta B, Spano G, Drider D, Capozzi V, et al. Antimicrobial Properties, Functional Characterisation and Application of Fructobacillus fructosus and Lactiplantibacillus plantarum Isolated from Artisanal Honey. Probiotics Antimicrob Proteins. 2023 Oct;15(5):1406-23. doi: 10.1007/s12602-022-09988-4.
Chae M, Kim BJ, Na J, Kim SY, Lee JO, Kim Y jin, et al. Antimicrobial activity of Lactiplantibacillus plantarum APsulloc 331261 and APsulloc 331266 against pathogenic skin microbiota. Front Biosci-Elite. 2021 Dec 20;13(2):237. doi: 10.52586/e881.
Selegård R, Musa A, Nyström P, Aili D, Bengtsson T, Khalaf H. Plantaricins Markedly Enhance the Effects of Traditional Antibiotics Against Staphylococcus Epidermidis. Future Microbiol. 2019 Feb;14(3):195-205. doi: 10.2217/fmb-2018-0285.
Surve S, Shinde DB, Kulkarni R. Isolation, characterization and comparative genomics of potentially probiotic Lactiplantibacillus plantarum strains from Indian foods. Sci Rep. 2022;12:1940. doi: 10.1038/s41598-022-05850-3.
Ružić-Sabljić E, Maraspin V, Stupica D, Rojko T, Bogovič P, Strle F, et al. Comparison of MKP and BSK-H media for the cultivation and isolation of Borrelia burgdorferi sensu lato. Stevenson B, editor. PLOS ONE. 2017 Feb 7;12(2):e0171622. doi: 10.1371/journal.pone.0171622.
Schwameis M, Kündig T, Huber G, Von Bidder L, Meinel L, Weisser R, et al. Topical azithromycin for the prevention of Lyme borreliosis: a randomised, placebo-controlled, phase 3 efficacy trial. Lancet Infect Dis. 2017 Mar;17(3):322-9. doi: 10.1016/s1473-3099(16)30529-1.
Piesman J, Hojgaard A, Ullmann AJ, Dolan MC. Efficacy of an Experimental Azithromycin Cream for Prophylaxis of Tick-Transmitted Lyme Disease Spirochete Infection in a Murine Model. Antimicrob Agents Chemother. 2014 Jan;58(1):348-51. doi: 10.1128/aac.01932-13.
